knowledge -WSS

knowledge

author：knowledge 2025-10-02 22:15:26 - browse：641

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： 'Reaching a detente': STAT's Helen Branswell on covering Covid

explore

WSS

Couple fighting to bring baby home from Mexico are finally reunited

Why the Crimean Bridge is key to Russia's war in Ukraine

Case highlights the risks of experimental stem cell therapy

When prostate cancer spreads, where it goes matters

Resistance to cancer drugs: A new genetic explanation

HIV vaccine remains elusive. Immunologists keep trying new ideas

knowledge

knowledge

focus

Bright Health sells Medicare Advantage business to Molina

When prostate cancer spreads, where it goes matters

Heart attack and stroke risk calculators need revising

Couple fighting to bring baby home from Mexico are finally reunited

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why the Crimean Bridge is key to Russia's war in Ukraine

Medicare details structure of new drug price negotiation program

Addiction experts warn against a second 'war on drugs'

Dobbs anniversary: the lost opportunity of abortion as health care

Military medical care influenced by rank and race, new study finds

Wikipedia

Stanford president to resign after investigation of research

States increasingly look to regulate hospital facility fees

States increasingly look to regulate hospital facility fees

It's time to retire 'poor historian' from clinicians' vocabularies

Venture capitalist Bob Kocher on the state of digital health

NVIDIA and Google execs on the future of AI and drug discovery

explore

focus

explore

explore